EGFR and non-small cell lung carcinoma: After icotinib treatment, multiple nodular lesions continued to be alleviated, and PR was achieved after only 1 month’s treatment, suggesting that icotinib has a therapeutic effect on NSCLC with EGFR G719A/L833V compound mutation.